just a pointer that describes the approximate triptan market size.......
The migraine drugs market was dominated in 1999 by Imigran, Glaxo Wellcome's triptan. However, whilst Imigran exhibited sales in excess of $1,000m, the 6.4% decline in growth of sales between 1998 and 1999 is indicative of the competition Imigran now faces from the second generation triptans, including AstraZeneca's Zomig and Merck's Maxalt. Glaxo Wellcome must take comfort in the fact that its newer triptan, Naramig, demonstrated a growth rate of over 85% between 1998 and 1999.
(snip)
Datamonitor believes that the uptake of Zomig in the Japanese market will have a significant impact on sales of Zomig, since Datamonitor estimates that the prevalent migraine patient population is at least 8,800,000. Indeed, in 1998 the migraine market in Japan was $30.9m, whilst in the US, the market size was $1,162.6m......
the-infoshop.com
My opinion is that triptan sales could sky rocket, and that a long half life would be right up my alley. |
